ASX Announcement **19 February 2021**

H1 FY21 results investor briefing

SYDNEY Australia Friday, 19 February 2021 – Australian rapid blood test company Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is pleased to invite investors to attend an online briefing to discuss its results for the half-year ended 31 December 2020, which the Company plans to release on Tuesday, 23 February 2021.

The online briefing will be held on **Tuesday, 23 February 2021 at 11:00am (Sydney time).**

During the briefing, CEO and Managing Director, John Kelly and CFO, Will Souter will discuss highlights from the half-year result. This will be followed by a Q+A session.

Participants will need to pre-register ahead of time, via the following link:
https://us02web.zoom.us/webinar/register/WN_k4Uqh4rcRI2NhtY6UDKC7g

Once the registration form is completed, investors will receive a confirmation email with detail on how to access the briefing.

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com.